Department of Medicine, Faculty of Medicine, McMaster University, Hamilton, Ont, Canada.
Division of Allergy and Clinical Immunology, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
J Allergy Clin Immunol Pract. 2024 Sep;12(9):2439-2444.e4. doi: 10.1016/j.jaip.2024.06.004. Epub 2024 Jun 12.
Food allergies, particularly peanut, represent the predominant cause of anaphylaxis. Whereas early allergen introduction has emerged as a potential preventive strategy, the precise impact of recent guidelines on peanut-induced anaphylaxis rates in Canada remains unclear.
To assess the impact of the 2017 Addendum Guidelines for the Prevention of Peanut Allergy on peanut-induced anaphylaxis rates in Canada.
Using a comprehensive longitudinal registry capturing pediatric anaphylaxis presentations to the Montreal's Children's Hospital, we compared children with and without known peanut allergy who presented with peanut-induced anaphylaxis between 2011 and 2019 inclusive, excluding data beyond 2019 owing to the Coronavirus disease 2019 (COVID-19) pandemic. We calculated rates of peanut-induced anaphylaxis presentations per 100,000 age-adjusted all-cause emergency department visits using 4-month intervals. Interrupted time series analysis was used to compare anaphylaxis rate trends before and after 2017 for children ages 0 to 2 and 3 to 17 years.
We examined 2,011 cases of pediatric anaphylaxis, including 429 (21%) triggered by peanuts. Compared with pre-guideline estimates, the yearly rate of change of peanut anaphylaxis rates decreased by 7.96 (95% confidence interval -14.57 to -1.36; P = .018) after 2017 among patients with new-onset anaphylaxis in children 2 years of age or younger (n = 109). No significant changes were identified for older patients ages 3 to 17, or in patients with known peanut allergy.
Early introduction guidelines in Canada are associated with a reduced risk of new-onset peanut-induced anaphylaxis in young children within a single center in Montreal. Further research is required to assess the impact on a wider population and other food allergens.
食物过敏,尤其是花生过敏,是引发过敏反应的主要原因。虽然早期过敏原引入已成为一种潜在的预防策略,但最近的指南对加拿大花生过敏引发过敏反应率的具体影响仍不清楚。
评估 2017 年《花生过敏预防补充指南》对加拿大花生过敏引发过敏反应率的影响。
利用一项全面的纵向登记处,该登记处记录了蒙特利尔儿童医院所有儿童过敏反应的就诊情况,我们比较了在 2011 年至 2019 年间因摄入花生而出现过敏反应的、有和无已知花生过敏的儿童,排除了 2019 年以后因 COVID-19 大流行的数据。我们使用 4 个月的间隔计算了每 100,000 名年龄调整的所有原因急诊就诊中因摄入花生而出现过敏反应的发生率。使用中断时间序列分析比较了 0 至 2 岁和 3 至 17 岁儿童在 2017 年前后过敏反应率趋势。
我们共研究了 2011 例儿科过敏反应病例,其中 429 例(21%)由花生引发。与指南发布前的估计相比,在 2017 年之后,2 岁及以下新发过敏反应患儿(n=109)的花生过敏反应年变化率降低了 7.96(95%置信区间-14.57 至-1.36;P=0.018)。对于年龄较大的 3 至 17 岁患者或已知有花生过敏的患者,未发现明显变化。
加拿大早期引入指南与蒙特利尔单个中心的幼儿新发花生过敏风险降低有关。需要进一步研究来评估对更广泛人群和其他食物过敏的影响。